HEALTH● LOWAug 13 · Aug 13, 2026, 6:59 PM
Cellectar targets mid-2027 accelerated approval NDA for iopofosine in WM, backed by up to $140M financing
Seeking Alpha Tech
Cellectar aims for accelerated FDA approval by mid-2027 for iopofosine in WM, supported by up to $140 million in financing. This indicates a key strategic move for the company and its drug development.
GlobeAlert aggregates and classifies open sources; the story above belongs to its publisher. Summaries are machine-generated from the source text.
More in Health
HEALTH1h ago The health system in Nepal is not prepared for this upr.org · United StatesHEALTH1h agoEmotional Resilience with ADHD : Coping with Dysregulated Feelingsadditudemag.com · United StatesHEALTH1h agoBradley Riches Shares His Story of Surviving a Suicide Attemptinstinctmagazine.com · United StatesHEALTH1h agoHigh TDS , bad taste or borewell water ? Dont buy a purifier until you know thislivemint.com · India